MétaCan
Menu
Retour à la cohorte
Enregistrement W4391545301 · doi:10.1016/j.ebiom.2024.104991

Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis

2024· review· en· W4391545301 sur OpenAlexafffund
James Yarmolinsky, Jamie Robinson, Daniela Mariosa, Ville Karhunen, Jian Huang, Niki Dimou, Neil Murphy, Kimberley Burrows, Emmanouil Bouras, Karl Smith‐Byrne, Sarah J. Lewis, Tessel E. Galesloot, Lambertus A. Kiemeney, Sita H. Vermeulen, Paul Martin, Demetrius Albanes, Lifang Hou, Polly A. Newcomb, Emily White, Alicja Wolk, Anna H. Wu, Loı̈c Le Marchand, Amanda I. Phipps, Daniel D. Buchanan, Maria Teresa Landi, Victoria L. Stevens, Neil E. Caporaso, Paul Brennan, Christopher I. Amos, Sanjay Shete, Heike Bickeböller, Angela Risch, Richard Houlston, Stephen Lam, Adonina Tardón, Chu Chen, Stig E. Bojesen, H. E. Wichmann, David C. Christiani, Gad Rennert, Susanne M. Arnold, John K. Field, Olle Melander, Hans Brunnström, Geoffrey Liu, Angeline S. Andrew, Hongbing Shen, Shanbeh Zienolddiny, Kjell Grankvist, Mikael Johansson, M. Dawn Teare, Yun Chul Hong, Jian‐Min Yuan, Philip Lazarus, Matthew B. Schabath, Melinda C. Aldrich, Rosalind A. Eeles, Christopher A. Haiman, Zsofia Kote‐Jarai, Fredrick R. Schumacher, Sara Benlloch, Ali Amin Al Olama, Kenneth Muir, Sonja I. Berndt, David V. Conti, Fredrik Wiklund, Stephen J. Chanock, Catherine M. Tangen, Jyotsna Batra, Judith A. Clements, Henrik Grönberg, Nora Pashayan, Johanna Schleutker, Stephanie J. Weinstein, Catharine West, Lorelei A. Mucci, Géraldine Cancel‐Tassin, Stella Koutros, Karina D. Sørensen, Eli Marie Grindedal, David E. Neal, Freddie C. Hamdy, Jenny Donovan, Ruth C. Travis, Robert J. Hamilton, Sue A. Ingles, Barry S. Rosenstein, Yong‐Jie Lu, Graham G. Giles, Robert J. MacInnis, Adam S. Kibel, Ana Vega, Manolis Kogevinas, Kathryn L. Penney, Jong Y. Park, Janet L. Stanfrod, Cezary Cybulski, Børge G. Nordestgaard, Sune F. Nielsen, Hermann Brenner, Christiane Maier, Christopher J. Logothetis, Esther M. John, Manuel R. Teixeira, Susan L. Neuhausen, Kim De Ruyck, Azad Razack, Lisa F. Newcomb, Davor Lessel, Radka Kaneva, Nawaid Usmani, Frank Claessens, Paul A. Townsend, Jose E. Castelao, Monique J. Roobol, F. Ménégaux, Kay-Tee Khaw, Lisa Cannon‐Albright, Hardev Pandha, Stephen N. Thibodeau, David J. Hunter, Peter Kraft, William J. Blot, Elio Ríboli, Sizheng Steven Zhao, Dipender Gill, Mark P. Purdue, George Davey Smith, Karl‐Heinz Herzig, Marjo‐Riitta Järvelin, Chris Amos, Rayjean J. Hung, Abbas Dehghan, Marc J. Gunter, Richard M. Martin

Notice bibliographique

RevueEBioMedicine · 2024
Typereview
Langueen
DomaineMedicine
ThématiqueInflammatory Biomarkers in Disease Prognosis
Établissements canadiensLunenfeld-Tanenbaum Research InstitutePublic Health OntarioUniversity of TorontoInstitute of Cancer Research
Organismes subventionnairesDepartment of Epidemiology and Biostatistics, University of California, San FranciscoDivision of Cancer Epidemiology and Genetics, National Cancer InstituteNational Institute of Diabetes and Digestive and Kidney DiseasesNational Human Genome Research InstituteNational Heart, Lung, and Blood InstituteSchool of Public Health, Imperial College LondonWageningen University and ResearchInstituto de Salud Carlos IIIMedical Research CouncilCanadian Cancer Society Research InstituteBiobanco VascoJunta de Castilla y LeónXunta de GaliciaWorld Cancer Research FundRegion SkåneNational Institute for Health and Care ResearchCenters for Disease Control and PreventionChonnam National University Hwasun HospitalMemorial Sloan-Kettering Cancer CenterCentre International de Recherche sur le CancerInstitut National Du CancerNational Health and Medical Research CouncilDeutsche KrebshilfeKarolinska InstitutetAssociazione Italiana per la Ricerca sul CancroUniversity of Maryland School of Public HealthConseil Régional des Pays de la LoireVetenskapsrådetLigue Contre le CancerCanadian Institutes of Health ResearchEuropean CommissionKnut och Alice Wallenbergs StiftelseNational Institute of Environmental Health SciencesSwedish Cancer FoundationMinistry of Health, Labour and WelfareUniversity Hospitals Bristol NHS Foundation TrustConsejería de Educación, Junta de Castilla y LeónMutuelle Générale de l'Education NationaleMinisterie van Volksgezondheid, Welzijn en SportCancerfondenFundación Científica Asociación Española Contra el CáncerMinisterio de Economía y CompetitividadNational Center for Advancing Translational SciencesBundesministerium für Bildung und ForschungAcademy of FinlandCancer Council VictoriaMedizinische Universität GrazInstitut Gustave-RoussyHerzfelder'sche FamilienstiftungGrantová Agentura České RepublikyEmory UniversityVicHealthFlorida Department of HealthNational Institutes of HealthDivision of Cancer Prevention, National Cancer InstituteGroupement des Entreprises Françaises dans la lutte contre le CancerAssociation Anne de Bretagne GenetiqueCentre Hospitalier Universitaire de NantesNIHR Imperial Biomedical Research CentreUniverzita Karlova v PrazeMcGill UniversityOntario Research FoundationGeneralitat de CatalunyaImperial College LondonFood Standards AgencyNational Cancer InstituteEuropean Regional Development FundEuropean Cooperation in Science and TechnologyGénome QuébecInstitut National de la Santé et de la Recherche MédicaleMatthias Lackas-StiftungMoffitt Cancer CenterUmeå UniversitetChonnam National UniversityCentres de Recerca de CatalunyaConsejería de Salud y Familias, Junta de AndalucíaCanadian Cancer SocietyJohns Hopkins UniversityNational Institute on AgingNIHR Bristol Biomedical Research CentreOffice of Research Infrastructure Programs, National Institutes of HealthState of MarylandÖsterreichische ForschungsförderungsgesellschaftUniversity of South FloridaAmerican Institute for Cancer ResearchMinisterstvo Zdravotnictví Ceské RepublikyPelotoniaDeutsche ForschungsgemeinschaftUniversity of IowaNational Cancer CenterOntario Ministry of Research, Innovation and ScienceDeutsches KrebsforschungszentrumHarvard T.H. Chan School of Public HealthKræftens BekæmpelseVictorian Cancer AgencyUniversity of CambridgeStockholms Läns LandstingUniversity of PittsburghLung Cancer Research FoundationMike and Josie Harper Cancer Research InstituteNational Heart and Lung InstituteEno Scientific FoundationAgència de Gestió d'Ajuts Universitaris i de RecercaVersus ArthritisMaryland Department of HealthNational Research CouncilMarshfield Clinic Research FoundationAlbert Einstein Cancer CenterCancer Research UKXarxa de Bancs de Tumors de CatalunyaWorld Health OrganizationWereld Kanker Onderzoek FondsBrigham and Women's HospitalKarl-Franzens-Universität GrazUniversity of BristolDamon Runyon Cancer Research FoundationU.S. Department of Health and Human ServicesAmerican Cancer Society
Mots-clésMendelian randomizationMedicineCancerOncologyBioinformaticsGeneticsInternal medicineBiologyGenotypeGeneGenetic variants

Résumé

récupéré en direct d'OpenAlex

Background Tumour-promoting inflammation is a "hallmark" of cancer and conventional epidemiological studies have reported links between various inflammatory markers and cancer risk. The causal nature of these relationships and, thus, the suitability of these markers as intervention targets for cancer prevention is unclear. Methods We meta-analysed 6 genome-wide association studies of circulating inflammatory markers comprising 59,969 participants of European ancestry. We then used combined cis -Mendelian randomization and colocalisation analysis to evaluate the causal role of 66 circulating inflammatory markers in risk of 30 adult cancers in 338,294 cancer cases and up to 1,238,345 controls. Genetic instruments for inflammatory markers were constructed using genome-wide significant ( P < 5.0 × 10 −8 ) cis -acting SNPs (i.e., in or ±250 kb from the gene encoding the relevant protein) in weak linkage disequilibrium (LD, r 2 < 0.10). Effect estimates were generated using inverse-variance weighted random-effects models and standard errors were inflated to account for weak LD between variants with reference to the 1000 Genomes Phase 3 CEU panel. A false discovery rate (FDR)-corrected P -value (" q -value") <0.05 was used as a threshold to define "strong evidence" to support associations and 0.05 ≤ q -value < 0.20 to define "suggestive evidence". A colocalisation posterior probability (PPH 4 ) >70% was employed to indicate support for shared causal variants across inflammatory markers and cancer outcomes. Findings were replicated in the FinnGen study and then pooled using meta-analysis. Findings We found strong evidence to support an association of genetically-proxied circulating pro-adrenomedullin concentrations with increased breast cancer risk (OR: 1.19, 95% CI: 1.10–1.29, q -value = 0.033, PPH 4 = 84.3%) and suggestive evidence to support associations of interleukin-23 receptor concentrations with increased pancreatic cancer risk (OR: 1.42, 95% CI: 1.20–1.69, q -value = 0.055, PPH 4 = 73.9%), prothrombin concentrations with decreased basal cell carcinoma risk (OR: 0.66, 95% CI: 0.53–0.81, q -value = 0.067, PPH 4 = 81.8%), and interleukin-1 receptor-like 1 concentrations with decreased triple-negative breast cancer risk (OR: 0.92, 95% CI: 0.88–0.97, q -value = 0.15, PPH 4 = 85.6%). These findings were replicated in pooled analyses with the FinnGen study. Though suggestive evidence was found to support an association of macrophage migration inhibitory factor concentrations with increased bladder cancer risk (OR: 2.46, 95% CI: 1.48–4.10, q -value = 0.072, PPH 4 = 76.1%), this finding was not replicated when pooled with the FinnGen study. For 22 of 30 cancer outcomes examined, there was little evidence ( q -value ≥0.20) that any of the 66 circulating inflammatory markers examined were associated with cancer risk. Interpretation Our comprehensive joint Mendelian randomization and colocalisation analysis of the role of circulating inflammatory markers in cancer risk identified potential roles for 4 circulating inflammatory markers in risk of 4 site-specific cancers. Contrary to reports from some prior conventional epidemiological studies, we found little evidence of association of circulating inflammatory markers with the majority of site-specific cancers evaluated. Funding Cancer Research UK (C68933/A28534, C18281/A29019, PPRCPJT∖100005), World Cancer Research Fund (IIG_FULL_2020_022), National Institute for Health Research (NIHR202411, BRC-1215-20011), Medical Research Council (MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/6, and MC_UU_00011/4), Academy of Finland Project 326291, European Union's Horizon 2020 grant agreement no. 848158 (EarlyCause), French National Cancer Institute (INCa SHSESP20, 2020-076), Versus Arthritis (21173, 21754, 21755), National Institutes of Health (U19 CA203654), National Cancer Institute (U19CA203654).

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction distillée sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.

score de la tête « metaresearch » (Codex)0,002
score de la tête « metaresearch » (Gemma)0,001
Version: codex-gemma-dda1882f352aStatut de validation: machine_predicted_unvalidated
Catégories candidatesMéta-épidémiologie (sens strict)
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Autre devis · Signal consensuel: aucune
GenreSignal candidat: Synthèse · Signal consensuel: Synthèse
Score de désaccord entre enseignants0,712
Score d'incertitude au seuil1,000

Scores Codex et Gemma par catégorie

CatégorieCodexGemma
Métarecherche0,0020,001
Méta-épidémiologie (sens strict)0,0010,001
Méta-épidémiologie (sens large)0,0030,001
Bibliométrie0,0020,003
Études des sciences et des technologies0,0000,000
Communication savante0,0000,000
Science ouverte0,0000,000
Intégrité de la recherche0,0010,001
Charge utile insuffisante (le modèle a refusé de juger)0,0000,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,018
Tête enseignante GPT0,332
Écart entre enseignants0,314 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.

Devis d'étudeAutre devis
Domainenon disponible
GenreSynthèse

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations46
Publié2024
Routes d'admission2
Résumé présentoui

Explorer davantage

Même revueEBioMedicineMême sujetInflammatory Biomarkers in Disease PrognosisTravaux en français237 207